1190. Interactive Panelist
Session: Interactive Session: Direct Acting Antivirals for HCV: State-of-the-Art
Friday, October 19, 2012: 2:30 PM
Room: Ballroom 20 ABCD
Debika Bhattacharya, MD, Medicine, University of California, Los Angeles, Los Angeles, CA

Debika Bhattacharya, M.D. is an Assistant Professor of Medicine in the Division of Infectious Diseases at the University of California, Los Angeles. Her research interests include clinical outcomes in HIV/HCV coinfection, metabolic complications of HCV infection, and clinical trials of HCV antivirals. Her research also includes the assessment of HBV drug resistance in HIV/HBV coinfection and the study of mother-to-child transmission of of HBV in HIV/HBV coinfection. Dr. Bhattacharya completed her Infectious Diseases fellowship at Stanford University and was subsequently recruited to the University of California, Los Angeles. She is the Principal Investigator on 2 NIH grants evaluating HBV drug resistance and HBV MTCT in HIV/HBV coinfection and the principal investigator on 2 NIH funded awards examining metabolic outcomes in HCV infection. Dr. Bhattacharya is also involved in clinical research trials of novel agents for the treatment of HCV in both mono-infected and co-infected patients. Clinically, Dr. Bhattacharya manages patients with both HCV mono infection and HIV/HCV coinfection at the West Los Angeles VAMC. She is also an attending physician on the Inpatient Infectious Diseases Service at the Ronald Reagan Medical Center at UCLA. Dr. Bhattacharya serves on the AIDS Clinical Trials Group (ACTG) Hepatitis Transformative Science Group and is an invited member of the writing panel for the Adult NIH-CDC-HIVMA/IDSA Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents and a member of the Writing Panel for the CDC/NIH/HIVMA/IDSA/AAP Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children.

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 17th with the exception of research findings presented at the IDWeek press conferences.